NCT03364764View on ClinicalTrials.gov

Sirolimus Treatment for Refractory PRCA

PHASE4CompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

February 1, 2018

Primary Completion Date

February 1, 2019

Study Completion Date

May 1, 2021

Conditions
Pure Red Cell Aplasia
Interventions
DRUG

Sirolimus

On refractory PRCA patients, sirolimus was tried. Dosage: 2mg QD for the first day, then 1 mg QD. Medication time should last at least 6 months.

Trial Locations (1)

100730

Peking Union Medical College Hospital, Beijing

All Listed Sponsors
lead

Bing Han

OTHER

NCT03364764 - Sirolimus Treatment for Refractory PRCA | Biotech Hunter | Biotech Hunter